AZN (Pharmaceuticals) Stock Valuation & Fair Value Mixed on our tests
AZN (Pharmaceuticals) trades at a blended P/E of 16.1, about 7% above its historical normal valuation, with a forward growth estimate of 11.6% and a PEG of 1.38. Analysts' one-year estimates have been hit 91% of the time.
Valuation flags
- No notable valuation flags.
Frequently asked questions
Is AZN overvalued?
At a blended P/E of 16.1 versus its historical normal P/E of 15.0, AZN trades about 7% above its typical valuation, with a PEG of 1.38 on 11.6% forward growth. tickerseer currently rates it mixed on our tests.
What is AZN's fair value and PEG?
AZN trades at a blended P/E of 16.1 against a historical normal P/E of 15.0, a PEG of 1.38, and a forward growth estimate of 11.6%.
Has tickerseer's rating of AZN changed?
tickerseer's rating has been mixed on our tests since 2026-10-10.
Industry: Pharmaceuticals. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.